<?xml version='1.0' encoding='utf-8'?>
<document id="9726692"><sentence text="Lack of drug-drug interaction between cerivastatin and nifedipine."><entity charOffset="38-50" id="DDI-PubMed.9726692.s1.e0" text="cerivastatin" /><entity charOffset="55-65" id="DDI-PubMed.9726692.s1.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.9726692.s1.e0" e2="DDI-PubMed.9726692.s1.e0" /><pair ddi="false" e1="DDI-PubMed.9726692.s1.e0" e2="DDI-PubMed.9726692.s1.e1" /></sentence><sentence text="Cerivastatin is a novel, potent HMG-CoA reductase inhibitor"><entity charOffset="0-12" id="DDI-PubMed.9726692.s2.e0" text="Cerivastatin" /></sentence><sentence text=" It is primarily cleared via demethylation and hydroxylation with involvement of cytochrome P450 (CYP) 3A4 and subsequent biliary and renal excretion of the metabolites" /><sentence text=" Both cerivastatin and the dihydropyridine calcium antagonist nifedipine, which is primarily metabolized by CYP 3A4, are used concomitantly in the prevention and therapy of coronary heart disease"><entity charOffset="6-18" id="DDI-PubMed.9726692.s4.e0" text="cerivastatin" /><entity charOffset="27-50" id="DDI-PubMed.9726692.s4.e1" text="dihydropyridine calcium" /><entity charOffset="62-72" id="DDI-PubMed.9726692.s4.e2" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.9726692.s4.e0" e2="DDI-PubMed.9726692.s4.e0" /><pair ddi="false" e1="DDI-PubMed.9726692.s4.e0" e2="DDI-PubMed.9726692.s4.e1" /><pair ddi="false" e1="DDI-PubMed.9726692.s4.e0" e2="DDI-PubMed.9726692.s4.e2" /><pair ddi="false" e1="DDI-PubMed.9726692.s4.e1" e2="DDI-PubMed.9726692.s4.e1" /><pair ddi="false" e1="DDI-PubMed.9726692.s4.e1" e2="DDI-PubMed.9726692.s4.e2" /></sentence><sentence text=" To study the drug-drug interaction potential, the mutual effects of cerivastatin and nifedipine were investigated in a controlled, randomized, non-blind 3-way crossover study in healthy male subjects"><entity charOffset="69-81" id="DDI-PubMed.9726692.s5.e0" text="cerivastatin" /><entity charOffset="86-96" id="DDI-PubMed.9726692.s5.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.9726692.s5.e0" e2="DDI-PubMed.9726692.s5.e0" /><pair ddi="false" e1="DDI-PubMed.9726692.s5.e0" e2="DDI-PubMed.9726692.s5.e1" /></sentence><sentence text=" Single oral doses of 0" /><sentence text="3 mg cerivastatin or of 60 mg nifedipine were administered either alone or concomitantly under fasting conditions"><entity charOffset="5-17" id="DDI-PubMed.9726692.s7.e0" text="cerivastatin" /><entity charOffset="30-40" id="DDI-PubMed.9726692.s7.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.9726692.s7.e0" e2="DDI-PubMed.9726692.s7.e0" /><pair ddi="false" e1="DDI-PubMed.9726692.s7.e0" e2="DDI-PubMed.9726692.s7.e1" /></sentence><sentence text=" The mean AUC- and Cmax ratios (combination treatment versus monotherapy) including 90% confidence intervals were 1" /><sentence text="04 (0" /><sentence text="98 - 1" /><sentence text="10) and 1" /><sentence text="00 (0" /><sentence text="93 - 1" /><sentence text="07) for cerivastatin, and 0"><entity charOffset="8-20" id="DDI-PubMed.9726692.s14.e0" text="cerivastatin" /></sentence><sentence text="98 (0" /><sentence text="73 - 1" /><sentence text="32) and 0" /><sentence text="95 (0" /><sentence text="80 - 1" /><sentence text=" 13) for nifedipine, respectively"><entity charOffset="9-19" id="DDI-PubMed.9726692.s20.e0" text="nifedipine" /></sentence><sentence text=" Our results indicate that no mutual drug-drug interaction between cerivastatin and nifedipine occurs"><entity charOffset="67-79" id="DDI-PubMed.9726692.s21.e0" text="cerivastatin" /><entity charOffset="84-94" id="DDI-PubMed.9726692.s21.e1" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.9726692.s21.e0" e2="DDI-PubMed.9726692.s21.e0" /><pair ddi="false" e1="DDI-PubMed.9726692.s21.e0" e2="DDI-PubMed.9726692.s21.e1" /></sentence><sentence text="" /></document>